A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1300 participants.

Also called NCT02579031

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02579031
Other papers using this trial's data
  • Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial Lancet (London, England), 2019-10-05 DOI, PubMed 31488372
  • Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial JACC. Cardiovascular interventions, 2021-03-22 DOI, PubMed 33727005
  • Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial International journal of cardiology, 2021-07-01 DOI, PubMed 33887341

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02579031. Randomized; no masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2019-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Acronym
BIOSTEMI
Condition
Acute Coronary Syndrome
Intervention (Device)
Orsiro
Intervention (Device)
Xience
Lead sponsor
Insel Gruppe AG, University Hospital Bern (class: other)
Collaborator
University of Lausanne Hospitals (class: other)

Record details

Record id
cardio:ct-nct02579031
Content hash
4951f8d7a98c7a98f6c71406632f1071020e0e28850ae457d85461dee90f930a